Literature DB >> 17023427

Cloning and initial characterization of a new subunit for mammalian serine-palmitoyltransferase.

Thorsten Hornemann1, Stephane Richard, Markus F Rütti, Yu Wei, Arnold von Eckardstein.   

Abstract

Serine-palmitoyltransferase (SPT) catalyzes the rate-limiting step of the de novo synthesis of sphingolipids. SPT is considered to be a heterodimer composed of two subunits, SPTLC1 and SPTLC2. Here we report the identification of a novel, third, SPT subunit (SPTLC3) that shows 68% homology to the SPTLC2 subunit. Quantitative real-time PCR revealed that SPTLC3 expression is highly variable between different human tissues and cell lines. The highest expression was observed in placenta tissue and human trophoblast cell lines. The overexpression of SPTLC3 in Hek293 cells, which otherwise have very little endogenous SPTLC3, led to a 2- to 3-fold increase in cellular SPT activity. Silencing of SPTLC3 expression in HepG2 cells or human trophoblast cells by transfecting SPTLC3-specific siRNA resulted in a significant reduction of cellular SPT activity. The expression of two SPT isoforms could be a cellular mechanism to adjust SPT activity to tissue-specific requirements of sphingolipid synthesis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17023427     DOI: 10.1074/jbc.M608066200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  80 in total

1.  A disease-causing mutation in the active site of serine palmitoyltransferase causes catalytic promiscuity.

Authors:  Kenneth Gable; Sita D Gupta; Gongshe Han; Somashekarappa Niranjanakumari; Jeffrey M Harmon; Teresa M Dunn
Journal:  J Biol Chem       Date:  2010-05-26       Impact factor: 5.157

2.  Tsc10p and FVT1: topologically distinct short-chain reductases required for long-chain base synthesis in yeast and mammals.

Authors:  Sita D Gupta; Kenneth Gable; Gongshe Han; Anna Borovitskaya; Luke Selby; Teresa M Dunn; Jeffrey M Harmon
Journal:  J Lipid Res       Date:  2009-01-13       Impact factor: 5.922

Review 3.  PLP-dependent enzymes as entry and exit gates of sphingolipid metabolism.

Authors:  Florence Bourquin; Guido Capitani; Markus Gerhard Grütter
Journal:  Protein Sci       Date:  2011-09       Impact factor: 6.725

Review 4.  Sphingolipids in mitochondria.

Authors:  María José Hernández-Corbacho; Mohamed F Salama; Daniel Canals; Can E Senkal; Lina M Obeid
Journal:  Biochim Biophys Acta Mol Cell Biol Lipids       Date:  2016-09-30       Impact factor: 4.698

Review 5.  Sphingolipids, insulin resistance, and metabolic disease: new insights from in vivo manipulation of sphingolipid metabolism.

Authors:  William L Holland; Scott A Summers
Journal:  Endocr Rev       Date:  2008-05-01       Impact factor: 19.871

6.  Defective CFTR increases synthesis and mass of sphingolipids that modulate membrane composition and lipid signaling.

Authors:  Hiroko Hamai; Fannie Keyserman; Lynne M Quittell; Tilla S Worgall
Journal:  J Lipid Res       Date:  2009-01-14       Impact factor: 5.922

7.  Topological and functional characterization of the ssSPTs, small activating subunits of serine palmitoyltransferase.

Authors:  Jeffrey M Harmon; Dagmar Bacikova; Kenneth Gable; Sita D Gupta; Gongshe Han; Nivedita Sengupta; Niranjanakumari Somashekarappa; Teresa M Dunn
Journal:  J Biol Chem       Date:  2013-02-20       Impact factor: 5.157

8.  Myristate-derived d16:0 sphingolipids constitute a cardiac sphingolipid pool with distinct synthetic routes and functional properties.

Authors:  Sarah Brice Russo; Rotem Tidhar; Anthony H Futerman; L Ashley Cowart
Journal:  J Biol Chem       Date:  2013-03-25       Impact factor: 5.157

Review 9.  Sphingolipid De Novo Biosynthesis: A Rheostat of Cardiovascular Homeostasis.

Authors:  Linda Sasset; Yi Zhang; Teresa M Dunn; Annarita Di Lorenzo
Journal:  Trends Endocrinol Metab       Date:  2016-08-22       Impact factor: 12.015

Review 10.  An introduction to sphingolipid metabolism and analysis by new technologies.

Authors:  Yanfeng Chen; Ying Liu; M Cameron Sullards; Alfred H Merrill
Journal:  Neuromolecular Med       Date:  2010-08-03       Impact factor: 3.843

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.